Proactively evaluate Cytokinetics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
|Event Date||Event Type||Company Name||Ticker Symbol||Drug Name||Therapy Area||Indication||Source Type|
|30 Jun 2020||GDCTXXXX||Lorem||Lorem||Lorem||XXXX||Planned||Lorem|
|31 Mar 2020||Phase III Trial Results||Cytokinetics Inc; GenesisCare Clinical CRO Pty Ltd; Jinsheng Biotechnology Consulting (Shanghai) Co Ltd; Patheon NV||CYTK||omecamtiv mecarbil MR||Cardiovascular||Chronic Heart Failure; Congestive Heart Failure (Heart Failure); Systolic Heart Failure||Company Press Release|
|04 Mar 2020||Phase I Trial Completion||Cytokinetics Inc||CYTK||omecamtiv mecarbil MR||Cardiovascular||Systolic Heart Failure||Clinical Trial Registry|
|01 Dec 2019||Phase II Trial Initiation||Cytokinetics Inc||CYTK||aficamten||Cardiovascular||Hypertrophic Cardiomyopathy||Clinical Trial Registry|
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer